Sterling Capital Management’s Avalo Therapeutics AVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$20.6K Buy
1,343
+853
+174% +$15.7K ﹤0.01% 2188
2026
Q2
$9.06K Buy
+490
New +$7.75K ﹤0.01% 2277

Other funds holding AVTX

Sterling Capital Management's AVTX Position: Q3 2026 in Review

Sterling Capital Management increased its Avalo Therapeutics (AVTX) stake by 174% in Q3 2026, buying an estimated $15.7K and bringing the position to 1,343 shares worth $20.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2188.

Sterling Capital Management first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.

  • Sterling Capital Management held 1,343 shares of Avalo Therapeutics worth $20.6K as of Q3 2026.
  • Sterling Capital Management bought 853 Avalo Therapeutics shares in Q3 2026, an estimated $15.7K.
  • Avalo Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2188 holding.
  • Sterling Capital Management first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
  • 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.